
    
      The phase 1 dose escalation portion will establish the maximum tolerated dose (MTD) in
      patients with advanced solid tumors. Once the recommended phase 2 dose (RP2D) is established
      for both schedules, the phase 2 study will begin. Patients with relapsed/recurrent epithelial
      ovarian cancer will be randomized 1:1:1 to 3 treatment groups.
    
  